[go: up one dir, main page]

CY2016035I2 - Θεραπευτικη χρηση αντισωματων anti-cs1 - Google Patents

Θεραπευτικη χρηση αντισωματων anti-cs1

Info

Publication number
CY2016035I2
CY2016035I2 CY2016035C CY2016035C CY2016035I2 CY 2016035 I2 CY2016035 I2 CY 2016035I2 CY 2016035 C CY2016035 C CY 2016035C CY 2016035 C CY2016035 C CY 2016035C CY 2016035 I2 CY2016035 I2 CY 2016035I2
Authority
CY
Cyprus
Prior art keywords
antibodies
therapeutic use
therapeutic
Prior art date
Application number
CY2016035C
Other languages
English (en)
Other versions
CY2016035I1 (el
Original Assignee
Abbvie Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc. filed Critical Abbvie Biotherapeutics Inc.
Publication of CY2016035I2 publication Critical patent/CY2016035I2/el
Publication of CY2016035I1 publication Critical patent/CY2016035I1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Luminescent Compositions (AREA)
  • Glass Compositions (AREA)
CY2016035C 2003-05-08 2016-10-26 Θεραπευτικη χρηση αντισωματων anti-cs1 CY2016035I1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46921103P 2003-05-08 2003-05-08
US55762104P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
US55762004P 2004-03-29 2004-03-29
EP04760993A EP1624892B1 (en) 2003-05-08 2004-05-10 Therapeutic use of anti-cs1 antibodies

Publications (2)

Publication Number Publication Date
CY2016035I2 true CY2016035I2 (el) 2017-09-13
CY2016035I1 CY2016035I1 (el) 2017-09-13

Family

ID=33459144

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20111100687T CY1111958T1 (el) 2003-05-08 2011-07-14 Θεραπευτικη χρηση αντισωματων anti-csi
CY20141100872T CY1115671T1 (el) 2003-05-08 2014-10-23 Θεραπευτικη χρηση αντισωματων anti-cs1
CY2016035C CY2016035I1 (el) 2003-05-08 2016-10-26 Θεραπευτικη χρηση αντισωματων anti-cs1
CY20171100980T CY1119353T1 (el) 2003-05-08 2017-09-15 Θεραπευτικη χρηση αντισωματων anti-cs1

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20111100687T CY1111958T1 (el) 2003-05-08 2011-07-14 Θεραπευτικη χρηση αντισωματων anti-csi
CY20141100872T CY1115671T1 (el) 2003-05-08 2014-10-23 Θεραπευτικη χρηση αντισωματων anti-cs1

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20171100980T CY1119353T1 (el) 2003-05-08 2017-09-15 Θεραπευτικη χρηση αντισωματων anti-cs1

Country Status (25)

Country Link
US (8) US20050025763A1 (el)
EP (4) EP2371391B1 (el)
JP (4) JP4887152B2 (el)
KR (1) KR101268707B1 (el)
CN (1) CN1805755B (el)
AT (1) ATE506076T1 (el)
AU (2) AU2004238363B2 (el)
BE (1) BE2016C056I2 (el)
BR (1) BRPI0410129B8 (el)
CA (1) CA2523001C (el)
CY (4) CY1111958T1 (el)
DE (1) DE602004032328D1 (el)
DK (3) DK2853272T3 (el)
ES (2) ES2516840T3 (el)
FR (1) FR16C1012I2 (el)
HK (1) HK1208815A1 (el)
HU (2) HUE034908T2 (el)
LT (1) LT2853272T (el)
LU (1) LU93274I2 (el)
MX (1) MXPA05012011A (el)
NL (1) NL300838I2 (el)
PL (3) PL2853272T3 (el)
PT (3) PT1624892E (el)
SI (3) SI2853272T1 (el)
WO (1) WO2004100898A2 (el)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
HRP20150449T1 (xx) 2006-08-07 2015-06-05 Abbvie Biotherapeutics Inc. Metode lijeäśenja multiplog mijeloma primjenom kombiniranih terapija temeljenih na anti-cs1 antitijelima
BRPI0716475A2 (pt) * 2006-08-07 2016-05-03 Pdl Biopharma Inc composições e método anticorpos anti-sc1 para tratar múltiplos mielomas
WO2008019379A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
EP3384919A1 (en) 2008-06-02 2018-10-10 Dana Farber Cancer Institute, Inc. Cs1 peptides
CN102216332A (zh) * 2008-10-31 2011-10-12 艾伯特生物治疗学公司 抗-cs1抗体用于治疗罕见淋巴瘤的用途
EP2894226B1 (en) * 2009-01-08 2021-04-14 Bio-Rad Laboratories, Inc. Methods and compositions for improving efficiency of nucleic acids amplification reactions
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
US9150653B2 (en) * 2010-01-28 2015-10-06 Glaxo Group Limited CD127 binding proteins
MX367345B (es) 2010-02-24 2019-08-15 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
MY186591A (en) 2011-04-01 2021-07-29 Immunogen Inc Methods for increasing efficacy of folri cancer therapy
CA2883222C (en) 2012-08-31 2021-12-14 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
EP3919069A1 (en) 2012-11-05 2021-12-08 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
JP6449229B2 (ja) * 2013-03-15 2019-01-09 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｆｃ変異体
EP2970488A2 (en) * 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25 antibodies and their uses
CN105377897A (zh) * 2013-05-03 2016-03-02 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
EP3024482A4 (en) * 2013-07-24 2017-03-15 The General Hospital Corporation Methods for diagnosing and treating immune disease
HRP20211317T1 (hr) 2013-08-30 2021-11-26 Immunogen, Inc. Antitijela i analize za detekciju folat receptora 1
WO2015057674A1 (en) 2013-10-14 2015-04-23 Club Car, Llc Self-preloading shift lever
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015069785A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
EP3137498A1 (en) * 2014-05-02 2017-03-08 Cellectis Cs1 specific multi-chain chimeric antigen receptor
HUE048663T2 (hu) * 2014-06-17 2020-07-28 Medimmune Ltd Javított alfavbéta8 ellenanyagok
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2016049022A1 (en) * 2014-09-23 2016-03-31 Board Of Trustees Of Michigan State University Compositions and methods for modulating an immune response
CA2966005C (en) * 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
MX2017007097A (es) 2014-12-04 2017-09-05 Bristol Myers Squibb Co Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
DE102015102183B4 (de) * 2015-02-16 2018-03-01 Robert Bosch Automotive Steering Gmbh Lenkzwischenwelle für ein Kraftfahrzeug und Verfahren zum Betreiben einer Lenkzwischenwelle für ein Kraftfahrzeug
EP3258967A4 (en) 2015-02-20 2018-10-03 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
WO2016168766A1 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized chimeric receptor t cell switches and uses thereof
MX391581B (es) 2015-06-29 2025-03-04 Bristol Myers Squibb Co Regimenes de dosificacion inmunoterapeutica que comprenden pomalidomida y un anticuerpo anti-cs1 para el tratamiento de cancer.
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
CN108697791B (zh) 2015-11-03 2022-08-23 詹森生物科技公司 特异性结合pd-1的抗体及其用途
WO2018169999A1 (en) * 2017-03-13 2018-09-20 Intrinsic Lifesciences Llc Antibodies to human erythroferrone and uses thereof
US11124579B2 (en) 2017-03-29 2021-09-21 Agency For Science, Technology And Research Anti oligosaccharide antibody
AU2018287042A1 (en) 2017-06-20 2020-02-06 Centre National De La Recherche Scientifique - Cnrs - Immune cells defective for Suv39h1
KR102486090B1 (ko) 2017-08-07 2023-01-10 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
MX2020004239A (es) 2017-11-01 2020-09-09 Juno Therapeutics Inc Proceso para producir una composicion de celulas t.
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
PL3704230T3 (pl) 2017-11-01 2025-02-24 Juno Therapeutics, Inc. Proces wytwarzania kompozycji terapeutycznych z komórek zmodyfikowanych genetycznie
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
BR112020011144A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc formulação de meio livre de soro para o cultivo de células e métodos de uso da mesma
KR20250136416A (ko) 2017-12-08 2025-09-16 주노 쎄러퓨티크스 인코퍼레이티드 조작된 t 세포의 조성물의 제조방법
BR112020011223A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc marcadores fenotípicos para terapia celular e mé-todos relacionados
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
US12234280B2 (en) 2018-03-05 2025-02-25 Janssen Pharmaceutica Nv Anti-PHF-tau antibodies and uses thereof
EP3814369A1 (en) 2018-06-29 2021-05-05 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Tweak-receptor agonists for use in combination with immunotherapy of a cancer
WO2020033916A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
CN109406798A (zh) * 2018-10-29 2019-03-01 美康生物科技股份有限公司 肌酐酶法检测试剂盒
CN113614108A (zh) 2018-11-01 2021-11-05 朱诺治疗学股份有限公司 G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
IL263394A (en) * 2018-11-29 2020-05-31 Amit Ido Methods of activating dysfunctional immune cells and treatment of cancer
CN114025788A (zh) 2019-05-01 2022-02-08 朱诺治疗学股份有限公司 从经修饰的tgfbr2基因座表达重组受体的细胞、相关多核苷酸和方法
CN114007640A (zh) 2019-05-01 2022-02-01 朱诺治疗学股份有限公司 从修饰的cd247基因座表达嵌合受体的细胞、相关多核苷酸和方法
CN114222815A (zh) 2019-07-23 2022-03-22 记忆疗法公司 Suv39h1缺陷的免疫细胞
CN115298549A (zh) 2019-11-05 2022-11-04 百时美施贵宝公司 M蛋白测定及其用途
BR112022015523A2 (pt) * 2020-02-05 2022-09-27 Navaux Inc Anticorpos anti-hepsina e seus usos
CA3179800A1 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
US20230178239A1 (en) 2020-05-13 2023-06-08 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
KR20230074713A (ko) 2020-07-30 2023-05-31 엥스띠뛰 퀴리 Socs1에 결함이 있는 면역 세포
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
EP4337763A1 (en) 2021-05-10 2024-03-20 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
EP4346912A1 (en) 2021-05-25 2024-04-10 Institut Curie Myeloid cells overexpressing bcl2
JP2025501272A (ja) 2021-12-28 2025-01-17 ムネモ・セラピューティクス 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
KR20240137075A (ko) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물의 제조 방법
MX2024010003A (es) 2022-02-18 2024-09-30 Rakuten Medical Inc Moléculas de anticuerpo anti-ligando 1 de muerte programada (pd-l1), polinucleótidos que las codifican y métodos de uso.
US20250213614A1 (en) 2022-03-31 2025-07-03 Institut Curie Modified RELA Protein for Inducing Interferon Expression and Engineered Immune Cells with Improved Interferon Expression
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
CN115141825A (zh) * 2022-08-12 2022-10-04 武汉希望组生物科技有限公司 一种微小型昆虫基因组dna的提取方法
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
CN120344563A (zh) * 2022-12-02 2025-07-18 广州荔泰生物科技有限公司 人cs1 car-t细胞
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
US20260001951A1 (en) 2024-06-28 2026-01-01 Immunitybio, Inc. Anti-SLAMF7 Antibodies And Therapeutics

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004692A (en) 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
WO2001016318A2 (en) 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1996039518A1 (en) 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
WO1999063088A2 (en) 1998-06-02 1999-12-09 Genentech, Inc. Membrane-bound proteins and nucleic acids encoding the same
JP2001522239A (ja) 1997-03-21 2001-11-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ８７個のヒト分泌タンパク質
WO2000011150A1 (en) 1998-08-25 2000-03-02 Incyte Pharmaceuticals, Inc. Cell surface immunomodulators
CA2361293A1 (en) 1999-02-10 2000-08-17 Human Genome Sciences, Inc. 33 human secreted proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US7109292B2 (en) * 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3750000A (en) 1999-03-15 2000-10-04 Eos Biotechnology, Inc. Reusable low fluorescent plastic biochip
EP1210418B1 (en) 1999-06-02 2010-08-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001046260A2 (en) * 1999-12-23 2001-06-28 Bristol-Myers Squibb Company Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
PL358215A1 (en) * 2000-03-24 2004-08-09 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US20030215450A1 (en) 2000-05-26 2003-11-20 Blake Simon M Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
EA007388B1 (ru) * 2001-01-29 2006-10-27 Идек Фармасьютикалз Корпорейшн Модифицированные антитела и способы применения
CA2441840A1 (en) 2001-03-21 2002-11-28 Human Genome Sciences, Inc. Human secreted proteins
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003018621A2 (en) 2001-08-23 2003-03-06 Oxford Biomedica (Uk) Limited Genes
US20040038877A1 (en) 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US6478825B1 (en) * 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
US7041499B2 (en) * 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
CN102216332A (zh) 2008-10-31 2011-10-12 艾伯特生物治疗学公司 抗-cs1抗体用于治疗罕见淋巴瘤的用途
CN104010774B (zh) 2011-09-15 2017-10-13 康富真信息技术股份有限公司 用于自动生成机器人程序的系统和方法
WO2013123099A1 (en) 2012-02-13 2013-08-22 Radius Engineering Inc. Reusable cartridge for injection molding

Also Published As

Publication number Publication date
FR16C1012I2 (fr) 2019-01-11
CA2523001A1 (en) 2004-11-25
HK1208815A1 (en) 2016-03-18
JP2017019795A (ja) 2017-01-26
JP2014139187A (ja) 2014-07-31
DK2853272T3 (da) 2017-11-06
US20120064083A1 (en) 2012-03-15
KR101268707B1 (ko) 2013-05-29
PL2371391T3 (pl) 2015-01-30
JP5976288B2 (ja) 2016-08-23
JP4887152B2 (ja) 2012-02-29
LT2853272T (lt) 2017-10-10
US20160002335A1 (en) 2016-01-07
EP2853272A1 (en) 2015-04-01
US9175081B2 (en) 2015-11-03
US20050025763A1 (en) 2005-02-03
HUE034908T2 (hu) 2018-03-28
LU93274I2 (fr) 2016-12-27
US20090238827A1 (en) 2009-09-24
CY1119353T1 (el) 2018-02-14
DE602004032328D1 (de) 2011-06-01
CY1111958T1 (el) 2015-11-04
FR16C1012I1 (el) 2016-09-12
HK1089374A1 (en) 2006-12-01
SI2853272T1 (sl) 2017-10-30
US8008450B2 (en) 2011-08-30
PL1624892T3 (pl) 2011-09-30
EP1624892A4 (en) 2007-08-08
US8445646B2 (en) 2013-05-21
SI2371391T1 (sl) 2014-12-31
SI1624892T1 (sl) 2011-08-31
CN1805755A (zh) 2006-07-19
HK1163497A1 (en) 2012-09-14
US20100168397A1 (en) 2010-07-01
PT1624892E (pt) 2011-07-12
ES2516840T3 (es) 2014-10-31
PT2853272T (pt) 2017-08-30
EP2853272B1 (en) 2017-08-02
US20200031929A1 (en) 2020-01-30
EP1624892A2 (en) 2006-02-15
CY1115671T1 (el) 2017-01-25
EP2371391A1 (en) 2011-10-05
JP2012121878A (ja) 2012-06-28
EP3275463A1 (en) 2018-01-31
US8133981B2 (en) 2012-03-13
BRPI0410129B8 (pt) 2021-05-25
US20090238835A1 (en) 2009-09-24
AU2010214661B2 (en) 2012-05-17
ATE506076T1 (de) 2011-05-15
NL300838I2 (el) 2017-01-03
BRPI0410129A (pt) 2006-05-16
EP1624892B1 (en) 2011-04-20
JP6042834B2 (ja) 2016-12-14
AU2004238363A1 (en) 2004-11-25
AU2004238363B2 (en) 2010-05-27
US20140065063A1 (en) 2014-03-06
EP2371391B1 (en) 2014-07-23
PT2371391E (pt) 2014-10-30
BE2016C056I2 (el) 2023-08-09
DK2371391T3 (da) 2014-11-03
CN1805755B (zh) 2011-06-01
DK1624892T3 (da) 2011-08-08
WO2004100898A2 (en) 2004-11-25
US10442859B2 (en) 2019-10-15
PL2853272T3 (pl) 2018-01-31
ES2643289T3 (es) 2017-11-22
BRPI0410129B1 (pt) 2020-02-11
WO2004100898A3 (en) 2005-08-18
CA2523001C (en) 2013-12-31
CY2016035I1 (el) 2017-09-13
HUS1600042I1 (hu) 2016-11-28
AU2010214661A1 (en) 2010-09-16
JP2007503465A (ja) 2007-02-22
MXPA05012011A (es) 2006-02-03
KR20060018837A (ko) 2006-03-02

Similar Documents

Publication Publication Date Title
CY2016035I2 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
ATE465180T1 (de) Therapeutische anti-igfr1-antikörper- kombinationen
DK1572946T3 (da) Terapeutisk humant monoklonalt anti-IL-1R1-antistof
DE60315135D1 (de) Therapiesonde
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
NO20052914D0 (no) Terapeutiske forbindelser
IS8266A (is) Breytt mennsk IGF-1R mótefni
EE05505B1 (et) Personaalne teraapiasektsioon
EP1642377A4 (en) VIBRATION DEVICE
PL373333A1 (pl) Stosowanie przeciwciał skierowanych przeciw TNFalfa i innego leku
DK1587542T3 (da) Anvendelse af anti-CD100-antistoffer
JP2006502186A5 (ja) β-グルカンの使用
DE602004026081D1 (de) Therapeutische humanisierte antikörper gegen cd45-isoformen
DK1597171T3 (da) Terapeutisk mikroskum
NO20043305D0 (no) Preparation of lodixanol
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas
DE602004004262D1 (de) Ultraschallbehandlung von gewebematrices
NO20050689L (no) Terapeutisk anvendelse
DE502004005544D1 (de) Mikrodosiereinrichtung
EP1646401A4 (en) SPECIFIC HUMAN ANTIBODIES
DK2301576T3 (da) Terapeutisk anvendelse af anti-CS1-antistoffer
DE602004022100D1 (de) Stimulationshilfe
DE502004000494D1 (de) Schrittschaltwerk
FR2839258B1 (fr) Deambulateur-siege
FR2855730B1 (fr) Surmatelas de relaxation